Home›Compare›Ivim Health vs MyMenopauseRx

Ivim Health vs MyMenopauseRx: Which Is Better?

Head-to-head comparison of Ivim Health and MyMenopauseRx based on our independent scoring across trust, value, experience, product range, and reputation — plus real pricing for the treatments they both offer.

Our Verdict

MyMenopauseRx scores higher overall in our independent evaluation (61.3/100 vs 57.8/100), leading on trust & safety, product range. Ivim Health comes out ahead on value, experience, reputation. Ivim Health has the lower entry price (from $125/mo vs $150/mo), so the better value depends on which treatment you need.

GLP-1 telehealth platform with peer-reviewed clinical outcomes data, offering compounded semaglutide and tirzepatide alongside women's hormone therapy across 49 states.

Visit Ivim Health

Gynecologist-founded virtual menopause practice that bills most commercial insurance or charges $150 per self-pay visit, prescribing FDA-approved HRT, non-hormonal therapy and branded GLP-1s to local pharmacies.

Visit MyMenopauseRx

Score Breakdown

DimensionIvim HealthMyMenopauseRx
Overall Score57.8/10061.3/100 ✓
Trust & Safety30%55/10074/100 ✓
Value25%70/100 ✓58/100
Experience20%60/100 ✓58/100
Product Range15%35/10050/100 ✓
Reputation10%65/100 ✓55/100

At a Glance

Founded20212021
HeadquartersColumbus, OHChicago area, IL
Publicly tradedNoNo
Treatment categories33
Treatments listed43
Starting price$125/mo$150/mo

Pricing Where They Compete

Prices shown are based on our most recent research and may not reflect current pricing. Telehealth providers update their pricing frequently. Always verify pricing directly with the provider before purchasing.

CategoryIvim HealthMyMenopauseRx
Weight Loss / GLP-1$150–$175
Compounded Semaglutide (12-month plan)
—
Women's Health—$150
Virtual Menopause Visit (self-pay)
Hormone Therapy$125–$199
Women's Hormone Optimization
—

Ivim Health

+Peer-reviewed clinical data: 21.8% average weight loss at 68 weeks, published in Obesity Pillars
+Competitive compounded semaglutide pricing from $75/mo (medication only) on annual plan
+Comprehensive care: unlimited provider visits, health coaching, 24/7 clinical support included
−FDA Warning Letter (February 2026) for misleading product labeling — serious regulatory flag
−Restrictive refund policy: all fees non-refundable, restocking fees on cancellation
−Customer support shifted to chat-only; multi-day response waits reported
Read the full Ivim Health review →

MyMenopauseRx

+Founder and clinicians are named, and most hold Menopause Society certification (MSCP); patients can keep the same clinician
+In-network with major commercial plans, so many insured patients pay only a copay; $150 flat self-pay rate otherwise
+Prescribes FDA-approved therapies to the patient's local pharmacy, and labs can be ordered on demand at discounted self-pay rates
−No cash-pay medication pricing; the cost of HRT or branded GLP-1s depends on the patient's pharmacy and insurance
−Doesn't accept Medicare, Medicaid or HMO plans, and testosterone is offered only in Illinois
−Very thin public reviews (Trustpilot 3.3/5 on 4), including complaints of rushed visits and repeated charges
Read the full MyMenopauseRx review →

Ivim Health vs MyMenopauseRx — FAQ

Is Ivim Health better than MyMenopauseRx?

▾

MyMenopauseRx scores higher overall in our independent evaluation (61.3/100 vs 57.8/100), leading on trust & safety, product range. Ivim Health comes out ahead on value, experience, reputation. Ivim Health has the lower entry price (from $125/mo vs $150/mo), so the better value depends on which treatment you need.

Is Ivim Health or MyMenopauseRx cheaper?

▾

Ivim Health has the lower starting price (from $125/mo vs $150/mo for MyMenopauseRx). Starting prices are for the cheapest treatment each offers — compare the specific treatment you need, and check what each price includes.

What do Ivim Health and MyMenopauseRx both offer?

▾

Both platforms treat Weight Loss / GLP-1, Women's Health, Hormone Therapy. Ivim Health covers 3 treatment categories total and MyMenopauseRx covers 3.

Still deciding?